There are currently 14 active clinical trials seeking participants for Lung Neoplasms research studies. The states with the highest number of trials for Lung Neoplasms participants are California, Texas, Tennessee and Ontario.
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
NCT04738487
Recruiting
The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%, TPS ≥1% and TPS 1% to 49%; and (2) progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), in participants with PD-L1 TPS ≥1% and TPS ≥50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Boca Raton Regional Hospital ( Site 0004), Boca Raton, Florida +193 locations
Conditions: Lung Neoplasms, Non-Small-Cell Lung Carcinoma
Register for Updates
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
NCT05299606
Recruiting
This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone. The primary endpoint is Technique Efficacy, assessed 30-days post-ablation via CT imaging.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/19/2024
Locations: Stanford University School of Medicine, Stanford, California +9 locations
Conditions: Lung Neoplasms
Register for Updates
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
NCT02769962
Recruiting
Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood. Once inside cancer cells, the chemotherapy drug is released from the molecule. Olaparib is a drug that may stop cancer cells from repairing the DNA damage caused by chemotherapy. Researchers want to see how safe it is to give EP0057 and olaparib together and to see how well the combination treats a specif... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
Register for Updates
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377
Recruiting
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Southern Cancer Center, Mobile, Alabama +64 locations
Conditions: Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Register for Updates
TELESCOPE- TELEhealth Shared Decision-making COaching
NCT05491213
Recruiting
Hypothesis 1a: The investigators anticipate that navigator decision coaching, compared to enhanced usual care (EUC) will result in higher quality SDM for lung cancer screening (LCS )(primary outcome), greater knowledge of lung cancer screening benefits and harms, and lower decisional conflict. Hypothesis 1b: Compared to enhanced usual care (EUC), we expect that TELESCOPE will result in more screening discussions, increased initial for lung cancer screening (LCS) with low-dose CT scan (LDCT) upt... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Rutgers, Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Lung Neoplasms
Register for Updates
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
NCT06237881
Recruiting
To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/01/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
Register for Updates
Real World Registry for Use of the Ion Endoluminal System
NCT06004440
Recruiting
The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: University of California Davis Medical Center, Davis, California +12 locations
Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
Register for Updates
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
NCT01580982
Recruiting
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
02/02/2024
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Lung Neoplasms
Register for Updates
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
NCT04577599
Recruiting
Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.
Gender:
All
Ages:
Between 40 years and 54 years
Trial Updated:
01/17/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Lung Neoplasms, Lung Cancer
Register for Updates
Specimen Banking From Patients With Lung Cancer
NCT01585675
Recruiting
The primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translation research, which will enable the investigators to detect lung cancer earlier, develop better therapies and explore screening and prevention strategies.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
12/22/2023
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Lung Neoplasms
Register for Updates
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
NCT02549638
Recruiting
The study will utilize both retrospective and prospective data collection from patients that already had a bronchoscopy and lung resection or will have a bronchoscopy and lung resection for squamous cell carcinoma. The investigators plan to prospectively collect 5 bronchoscopic biopsies, 10ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Carcinoma, Squamous Cell, Carcinoma, Squamous, Squamous Cell Carcinoma, Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Register for Updates
Circulating Tumor Cells (CTC) in Lung Cancer
NCT02630615
Recruiting
The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/11/2023
Locations: Indiana University Health Hospital, Indianapolis, Indiana +1 locations
Conditions: Lung Neoplasms
Register for Updates